Race Oncology develops improved cancer cell treatment using bisantrene and decitabine.
Race Oncology's innovative cancer cell treatment breakthrough combines bisantrene with decitabine, enhancing the killing of multiple cancer cell types. This development may lead to a significant improvement in cancer treatment and could have a positive impact on the company's shares. Experienced writer and editor Jonathan Jackson, who has worked in print and digital media across various business and finance titles, covered the story.
May 14, 2024
3 Articles